The U.S. Electronic Drug Delivery Devices Market was valued at USD 24.0 billion in 2024, and is projected to reach USD 37.1 billion by 2030, rising at a CAGR of 7.50%. The growing demand for managing chronic conditions like diabetes, cancer-related pain, neuropathic pain, and contraceptive needs has contributed to the rise of the Electronic Drug Delivery Devices (EDDD) industry. These devices provide a controlled method of drug administration that is both more convenient and less painful, while also reducing the risk of side effects. They help ensure that drug levels remain within a specific range, known as the therapeutic window, for optimal effectiveness. The National Cancer Institute forecasts that around 2,001,140 new cancer cases will be diagnosed in the U.S. in 2024. Among these, breast cancer remains the most frequently diagnosed type of cancer in women.
In 2024, an estimated 26.8 million Americans were affected by asthma, including 4.5 million children. This contributes to millions of emergency department visits annually, resulting in tens of billions of dollars in healthcare expenses. In addition, approximately 11.7 million people, or 4.6% of adults, have been diagnosed with chronic obstructive pulmonary disease (COPD).
Patients increasingly prefer managing their health conditions at home, so there is a growing demand for drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering convenience and autonomy.
This product will be delivered within 2 business days.
In 2024, an estimated 26.8 million Americans were affected by asthma, including 4.5 million children. This contributes to millions of emergency department visits annually, resulting in tens of billions of dollars in healthcare expenses. In addition, approximately 11.7 million people, or 4.6% of adults, have been diagnosed with chronic obstructive pulmonary disease (COPD).
Patients increasingly prefer managing their health conditions at home, so there is a growing demand for drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering convenience and autonomy.
U.S. Electronic Drug Delivery Devices Market Highlights
- Based on product, the Implantable Drug Delivery Devices (IDDD) segment dominated the electronic drug delivery devices industry, accounting for the largest revenue share of 33.0% in 2024.
- These devices enable daily and monthly drug delivery, reducing the need for frequent dosing and checkups, making them ideal for busy individuals.
- The Smart Metered Dose Inhalers (SMDIs) segment is expected to grow at the fastest CAGR of 11.0% over the forecast period.
- Based on application, the diabetes segment led the electronic drug delivery devices industry with the largest revenue share in 2024.
- The oncology segment is estimated to grow at the largest CAGR over the forecast period.
- The rising number of cancer cases fuels the growth as these devices offer a superior alternative to traditional injections, revolutionizing drug delivery by effectively improving the bioavailability and enabling precise targeting of therapeutic agents directly to cancerous tissues.
- In April 2025, Abbott introduced a next-generation delivery system for its Proclaim DRG neurostimulation system. The system is expected to streamline the procedure for implanting a system in patients suffering from CRPS Type 1 and CRPS Type 2 of the lower extremities.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Electronic Drug Delivery Devices Market Variables, Trends, & Scope
Chapter 4. U.S. Electronic Product Delivery Devices Market: Product Business Analysis
Chapter 5. U.S. Electronic Drug Delivery Devices Market: Application Business Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this U.S. Electronic Drug Delivery Devices market report include:- Medtronic
- BD
- Insulet Corporation
- Tandem Diabetes Care, Inc.
- Eli Lilly and Company
- Novo Nordisk A/S
- Johnson & Johnson Services, Inc.
- United Therapeutics Corporation
- Abbott
- AstraZeneca
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 24 Billion |
| Forecasted Market Value ( USD | $ 37.1 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
